Clinical trials: Stomach Tumor
Lymphoma
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric…
- Trial name
- NCT00003151
- Testing
- bismuth subcitrate, amoxicillin, clarithromycin
- Where
- 22 sites in United Kingdom
- Volunteers
- 96 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
HER2+ breast and gastric cancer patients' survival is significantly improved by trastuzumab alone or in combination with chemotherapy.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- CONTRAST (NCT05555251)
- Testing
- BI-1607, Trastuzumab
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 18 people
- Sponsor
- BioInvent International AB
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma
- Trial name
- NCT07903415
- Testing
- PF-08098488
- Where
- 2 sites in United States
- Volunteers
- 280 people
- Sponsor
- Pfizer
Gastric Carcinoma
Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy
This study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.
- Trial name
- zypg001 (NCT06728891)
- Testing
- In addition to routine diagnosis and treatment, no additional intervention measures were taken.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jichao Qin
Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma
iTTo for Treatment Naive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This study will evaluate the safety and feasibility of Irinotecan, Trifluridine/Tipiracil (TAS-102) and Oxaliplatin (iTTo) for treatment naïve advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT04808791
- Testing
- Irinotecan, Oxaliplatin, TAS 102 (Trifluridine/Tipiracil)
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- AHS Cancer Control Alberta
Gastric Cancer, COVID-19 Pandemic
The Impact of COVID-19 Pandemic on Clinical Presentation and Staging of Gastric Cancer
This was a retrospective case-control study designed and conducted under the approval of the ethic committee of Tehran University of Medical Sciences.
- Conditions
- Gastric Cancer, COVID-19 Pandemic, Peritoneal Metastases
- Trial name
- NCT05130710
- Testing
- staging laparoscopy
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Tehran University of Medical Sciences
Breast Cancer, Gastric/Gastroesophageal Junction Cancer
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
This is an open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03847168
- Testing
- KN026
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Gastric Adenocarcinoma
Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients
Gastric cancer remains one of the major causes of cancer deaths around the world,especially in Asia. For advanced gastric cancer,even if treated with chemotherapy,the prognosis is still poor, so the investigators urgently need an…
- Trial name
- NCT01641783
- Testing
- nanoparticle Albumin-Bound paclitaxel
- Volunteers
- 40 people
- Sponsor
- Yanqiao Zhang
Locally Advanced Gastric Cancer
Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer
In this study the patients with histological evidence of adenocarcinoma of the stomach will be screened and, if eligible, submitted to neo-adjuvant chemotherapy (NAC).
- Trial name
- Neo-D2plus (NCT03961373)
- Testing
- Gastrectomy with D2 lymphadenectomy, Gastrectomy with D2plus lymphadenectomy
- Where
- Italy
- Volunteers
- 539 people
- Sponsor
- University of Siena
Gastric Cancer
Laparoscopic vs Open Total Gastrectomy for Gastric Cancer
The aim of the present study is to demonstrated the the safety and feasibility of laparoscopic total gastrectomy comparing with open total gastrectomy.
- Trial name
- NCT05537129
- Testing
- Total Gastrectomy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fudan University
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Gastric Cancer
Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction
To assess whether the use of Seprafilm reduces the rate of small bowel obstruction in patients who underwent surgery for gastric cancer.
- Trial name
- NCT00529412
- Testing
- Seprafilm
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Nihon University
Gastric Cancer, Surgery
Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma
The objective of the trial is to compare disease-free survival between adjuvant capecitabine/cisplatin alone vs capecitabine/cisplatin with radiotherapy (chemoradiation) in curatively resected gastric cancer patients.
- Trial name
- NCT00323830
- Testing
- Capecitabine, cisplatin, Radiotherapy (+/-)
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Samsung Medical Center
Gastroesophageal Junction Adenocarcinoma, Stomach Neoplasms
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Phase II Study of Avelumab plus chemotherapy in the peri-operative treatment for patients with resectable Gastric cancer (GC) or Gastroesphageal Junction cancer (GEJC) The addition of Avelumab to the perioperative chemotherapy in…
- Trial name
- MONEO (NCT03979131)
- Testing
- Avelumab addition to perioperative chemotherapy in GC and GEJC
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Esophageal Neoplasms, Esophagectomy
Lifting of Gastric Tube Through Trans-substernal Versus Trans-esophageal Bed Path in MIE
Esophageal cancer (EC) is the eighth most common cancer and the sixth leading cause of cancer deaths worldwide. Minimally invasive esophagectomy (MIE) is regarded as a safe and effective management for resectable EC.
- Trial name
- NCT02309619
- Testing
- lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Gastric Cancer
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
The purpose of this study is to estimate objective response rates (ORRs) of pembrolizumab + oxaliplatin + TS-1 and pembrolizumab + cisplatin + TS-1, as first-line treatment for gastric cancer in programmed death-ligand 1 (PD-L1)…
- Trial name
- NCT03382600
- Testing
- Pembrolizumab, Oxaliplatin, TS-1
- Where
- 25 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.
This single arm study will assess the efficacy and safety of Xeloda in combination with oxaliplatin as first-line chemotherapy in patients with advanced and/or metastatic gastric cancer who have had no prior chemotherapy for…
- Trial name
- NCT00436241
- Testing
- Oxaliplatin, capecitabine [Xeloda]
- Where
- 13 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Stomach Neoplasms
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen])…
- Trial name
- NCT03675737
- Testing
- Pembrolizumab, Cisplatin, 5-fluorouracil
- Where
- 215 sites in United States, Argentina and 31 more
- Volunteers
- 1,579 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Neoplasms
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage…
- Trial name
- NCT00153881
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Esophageal Cancer, Gastric Cancer
Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, and giving them after surgery, may kill more tumor cells.
- Trial name
- NCT00003237
- Testing
- cisplatin, paclitaxel, surgical procedure
- Where
- 30 sites in United States, Puerto Rico and 1 more
- Volunteers
- 55 people
- Sponsor
- Eastern Cooperative Oncology Group